Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05994690 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revisedv3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 8 more changesShow less
    • Primary endpoints: 2 to 3
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 2023 to Jul 14, 2023
    • Interventions: Investigational Intervention (Drug), Standard Intervention (Drug) to Investigational Intervention Rc (Drug), Investigational Intervention Ri (Drug), Standard Intervention Rc (Drug), Standard Intervention Ri…
    • Eligibility criteria expanded, about 31 words
    • Study description revised
    • Collaborator revised
    • Study arms: 2 to 4
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.
Trial Details
NCT Number NCT05994690
Lead Sponsor Princess Maxima Center for Pediatric Oncology
Collaborators: European Commission
Conditions
(from sponsor)		 Acute Myeloid Leukemia in Children
Enrollment 905 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov